FMC Corporation

NYSE•FMC

CEO: Dr. Pierre R. Brondeau Ph.D.

Sector: Basic Materials

Industry: Agricultural Inputs

Listing Date: 1980-03-17

FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that includes insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control. The company markets its products through its own sales organization and through alliance partners, independent distributors, and sales representatives. It operates in North America, Latin America, Europe, the Middle East, Africa, and Asia. The company was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.

Contact Information

FMC Tower, 2929 Walnut Street Cira Centre South, Philadelphia, PA, 19104, United States

215-299-6000

www.fmc.com

Market Cap

$1.75B

P/E (TTM)

-0.8

27.8

Dividend Yield

13.0%

52W High

$44.78

52W Low

$12.17

52W Range

Rank31Top 21.6%

5.0

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Average • 5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$1.14B+0.00%

4-Quarter Trend

EPS

-$13.77+0.00%

4-Quarter Trend

FCF

$707.10M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

India Sale Charges Recorded $521.7M total adjustment recorded for India commercial business preparing for expected 2026 divestiture completion.

Adjusted EBITDA Decline Adjusted EBITDA reached $842.7M, reflecting a 7% decrease compared to $902.6M reported last year.

Major Goodwill Write-Off Recorded $1.36B goodwill impairment charge following significant Q4 2025 stock price decrease.

Debt Structure Optimization Issued $750.0M Subordinated Notes; used proceeds to redeem $500.0M of existing senior notes.

Risk Factors

Severe Stock Price Volatility Stock price fell over 70% from 52-week high; litigation risk increased following sharp Q4 2025 movement.

Generic Competition Pressure Increased generic presence and competitive pricing pressure impacting core portfolio product realization and margins.

Regulatory and Legal Exposure Approximately 11,070 asbestos claims pending; regulatory uncertainty affects product approval and sales globally.

Financing Costs Rising Long-term credit ratings downgraded below investment grade, potentially increasing future borrowing costs and limiting financing flexibility.

Outlook

Strategic Options Exploration Board authorized review of strategic options, including potential sale of the company, in early 2026.

2026 Balance Sheet Focus Priorities include paying down debt via asset sales and managing post-patent transition for Rynaxypyr active.

Project Foundation Implementation Restructuring program initiated to optimize cost structure, expecting $560M to $635M in total pre-tax charges.

Reduced Quarterly Dividend Quarterly dividend cut to $0.08 per share in October 2025 to further prioritize debt reduction goals.

Peer Comparison

Revenue (TTM)

SSL

$27.95B

-12.5%

$5.81B

-0.1%

HUN

$5.68B

-5.8%

Gross Margin (Latest Quarter)

USLM

48.0%

+3.7pp

ARMN

47.4%

+15.9pp

FMC

42.5%

-20.6pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SSL	$7.21B	51.8	1.6%	36.9%
BCPC	$5.47B	35.3	12.3%	11.2%
ARMN	$4.52B	48.0	7.2%	21.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

12.8%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 28, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data